People on the Move
Alzheon
Alzheon, a clinical-stage biopharmaceutical company developing drugs targeting the underlying causes of neurodegenerative diseases, including Alzheimer’s, has appointed a new member of the board of directors.
Franz Hefti is significantly experienced in drug discovery for central nervous system disorders, having been Chief Scientific Officer at Avid Radiopharmaceutcals when developed the amyloid imaging diagnostic for Alzheimer’s disease later acquired by Eli Lilly.
Hefti is currently CEO of Acumen Pharmaceuticals, a biopharmaceutical company. He has also served as executive VP of drug development at Rinat Neuroscience, acquired by Pfizer in 2006, and in management positions at Merck & Co. and Genentech.
Alzheon’s CEO Martin Tolar said Hefti’s expertise would help at a time when the company is developing ALZ-801, a therapy to help alleviate Alzheimer’s symptoms.